10 likes | 158 Views
Table 1 Overall survival improvement with single-agent temsirolimus compared with interferon ï¡ in the phase III Global ARCC trial.
E N D
Table 1 Overall survival improvement with single-agent temsirolimus compared with interferon in the phase III Global ARCC trial Figlin RA (2008) Mechanisms of Disease: survival benefit of temsirolimus validates a role for mTOR in the management of advanced RCCNat Clin Pract Oncol doi:10.1038/ncponc1173